Pharmacoeconomic profile of taxanes in advanced ovarian cancer

Messori, Andrea; Trippoli, Sabrina

doi:10.1097/00001813-199811000-00010

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this model, the survival analysis for the 2BMT group and for the chemotherapy group was based on a lifetime approach [9][10][11][12][13][14][15][16][17][18][19][20][21][22] that covered the entire post-relapse life expectancy of the patients; accordingly, all survival data were expressed as a combination of measured survival and predicted (or extrapolated) survival. This lifetime methodology that considers measured survival plus predicted survival is recommended by current guidelines for cost-effectiveness analysis.…”

Section: Methodsmentioning

confidence: 99%

“…23 In Model 2, the survival pattern for the two treatment options was quantified by determining the values of mean lifetime survival per patient (MLS) according to the Gom-pertz technique. [9][10][11][12][13][14][15][16][17][18][19][20] This latter technique employs an extrapolation to infinity of the survival curve for calculating both the area under the survival curve (AUC) and the corresponding MLS. 15 Cost data were obtained from published information and were introduced in a simplified analysis that estimated the incremental cost per patient between the two treatment options.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia

Messori

Bosi

Bacci

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The therapeutic options for patients with acute leukemia who relapse after the initial transplant include second bone marrow transplantation (2BMT) and conventional chemotherapy (CC). In this work, we conducted an analysis of published survival data and we evaluated the cost-effectiveness of 2BMT in comparison with CC. We retrieved survival information on 167 patients treated with 2BMT and 299 patients treated with CC. Survival figures were derived from individual patient data and were compared between 2BMT and CC. The mean lifetime survival (MLS) was estimated for each of the two patient cohorts using standard techniques of survival-curve extrapolation. The cost data of patients given 2BMT or CC were estimated from published data. Our analysis of individual survival data showed that 2BMT improved survival at levels of statistical significance (survival gain = 19.6 months per patient). Using an incremental cost of $90 000 per patient, the costeffectiveness ratio of 2BMT in comparison with CC was calculated as $52 215 discounted dollars per discounted life year gained. Our results indicate that, in patients with acute leukemia who relapse after their first transplant, 2BMT significantly prolongs survival in comparison with CC and seems to have an acceptable cost-effectiveness profile. Keywords: acute leukemia; second bone marrow transplantation; cost-effectiveness analysisIn patients with acute leukemia who have received an allogeneic bone marrow transplant, relapse implies a grim prognosis. To improve survival in these patients, a second allogeneic bone marrow transplant (2BMT) has been proposed as a more effective salvage intervention than conventional chemotherapy. [1][2][3][4][5][6][7][8] Six open uncontrolled studies [1][2][3][4][5][6] have thus far assessed the impact of 2BMT on survival, whereas at least two large-scale uncontrolled studies reported survival information for patients treated with a first allogeneic transplant and with conventional chemotherapy after relapse. In our work, seven of these studies [1][2][3][4][5]7,8 were utilized to conduct a retrospective survival analysis and to evaluate the cost-effectiveness ratio of 2BMT in comparison with conventional chemotherapy. Methods Study designOur study was aimed at evaluating survival and cost of the two following therapeutic options for patients with acute leukemia who relapse after the first allogeneic transplant: (1) 2BMT; (2) standard salvage chemotherapy.Our analysis consisted of three sequential phases: (1) literature search (from January 1985 to June 1998) of the clinical trials that evaluated survival for these two therapeutic options; (2) survival analysis with meta-analytic pooling of the results from the trials and with statistical testing; (3) cost-effectiveness analysis.Our survival meta-analysis was conducted through the following procedure (Model 1): firstly, the individual survival data were retrieved from the patient cohorts enrolled in the various studies; then, the survival difference between 2BMT vs conventional chemot...

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia

Messori

Bosi

Bacci

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

L’utilizzo di modelli decisionali per le valutazioni economiche dei farmaci in Italia: stato dell’arte e prospettive future

Cicchetti

Manca

Ruggeri

2007

Pharmacoeconomics-Ital-Res-Articles

View full text Add to dashboard Cite

Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review

Poonawalla

Parikh

et al. 2015

PharmacoEconomics

View full text Add to dashboard Cite

Despite varying methodological approaches and multiple sources for cost and effectiveness inputs, this systematic review demonstrated that standard platinum-taxane combination chemotherapy for first-line treatment was most cost-effective. There was unanimous agreement that bevacizumab was not a cost-effective front-line therapy compared with platinum-taxane combination for the overall ovarian cancer population, though its use in the high-use population may yield better value. For second-line treatment, platinum-based chemotherapy remained cost-effective among patients with recurrent platinum-sensitive disease, while there was limited evidence to conclude the most valuable treatment alternative among patients with recurrent platinum-resistant disease. Future research incorporating real-world data is essential to corroborate findings from trial-based economic evaluations. In addition, for improving consistency in reporting and quality of studies, incorporating QALYs in this population is important, especially since chemotherapy is administered for lengthy periods of time.

show abstract

Pharmacoeconomic profile of taxanes in advanced ovarian cancer

Cited by 6 publications

References 0 publications

Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia

Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia

L’utilizzo di modelli decisionali per le valutazioni economiche dei farmaci in Italia: stato dell’arte e prospettive future

Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review

Contact Info

Product

Resources

About